Kiprop 40 Tablet SR contains Propranolol 40mg, a non-selective beta-adrenergic receptor blocker used primarily in the management of cardiovascular conditions. Propranolol exerts its therapeutic effects by competitively blocking beta-1 and beta-2 adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. This sustained-release formulation ensures a gradual release of the active ingredient, providing prolonged therapeutic action and improved patient compliance through once-daily dosing. Kiprop 40 Tablet SR is indicated for the treatment of hypertension, angina pectoris, cardiac arrhythmias, and prevention of myocardial infarction. Additionally, it is utilized in managing essential tremor, migraine prophylaxis, and certain types of anxiety. The drug is contraindicated in patients with asthma, severe bradycardia, or uncompensated cardiac failure. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances, while serious side effects may involve bronchospasm and heart block. Caution is advised when administering to patients with diabetes or peripheral vascular disease. Regular monitoring of heart rate and blood pressure is recommended during therapy. Kiprop 40 Tablet SR should be used under medical supervision, with dosage adjustments tailored to individual patient response and clinical condition.